Trexquant Investment LP Purchases 545,677 Shares of 10x Genomics $TXG

Key Points

• Trexquant Investment LP significantly increased its stake in 10x Genomics by 91.8%, now holding approximately 1,140,288 shares worth about $9.95 million.
• 10x Genomics reported earnings of $0.28 per share, surpassing analysts' expectations, with revenue of $172.91 million for the quarter, indicating a 12.9% year-over-year growth.
• Institutional investors collectively own 84.68% of 10x Genomics, reflecting strong interest from the investment community amid varying analyst ratings, including six buy and six hold ratings.

Trexquant Investment LP increased its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 91.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,140,288 shares of the company's stock after purchasing an additional 545,677 shares during the period. Trexquant Investment LP owned 0.93% of 10x Genomics worth $9,955,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of TXG. GAMMA Investing LLC lifted its position in 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares during the period. GF Fund Management CO. LTD. acquired a new position in 10x Genomics during the 4th quarter valued at about $32,000. Signaturefd LLC lifted its position in 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the period. Whittier Trust Co. acquired a new position in 10x Genomics during the 1st quarter valued at about $41,000. Finally, PNC Financial Services Group Inc. lifted its position in 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after purchasing an additional 3,119 shares during the period. Institutional investors own 84.68% of the company's stock.

10x Genomics Stock Up 1.7%

Shares of TXG traded up $0.23 during trading hours on Thursday, reaching $13.57. The stock had a trading volume of 1,709,156 shares, compared to its average volume of 2,840,047. The firm has a 50-day moving average of $13.10 and a 200 day moving average of $10.74. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.38. The company has a market cap of $1.69 billion, a P/E ratio of -19.39 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. During the same period in the previous year, the firm earned ($0.32) EPS. 10x Genomics's quarterly revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares of the company's stock, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is owned by company insiders.

Analysts Set New Price Targets

TXG has been the topic of a number of research reports. Barclays restated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Bank of America upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Thursday, June 26th. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday, August 30th. Finally, UBS Group upped their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $13.54.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.